1. Introduction {#sec1}
===============

Schizophrenia is a chronic and degenerative disease, with an overall lifetime risk of 1%. Despite its high prevalence, the pathogenesis of schizophrenia is not clear \[[@B58], [@B7]\]. Current antipsychotics are generally successful in treating positive symptoms (e.g., hallucinations and delusions) but have limited effect on the reduction of negative and cognitive symptoms and have side effects \[[@B36]--[@B67]\]. Therefore, there is a need for new therapeutic agents with fewer side effects. The side effects accompanying the use of synthetic drugs, together with their acquisition cost and supply shortage, have recently increased people\'s interest in using medicinal plants. Aromatherapy, an alternative type of medicine which uses medicinal plants, is widely used for the management of chronic pain, depression, anxiety, insomnia, and stress-related disorders \[[@B43], [@B85]\]. However, the scientific basis underlying the mechanism of action of many medicinal plants and essential oils remains unclear \[[@B85], [@B41]\]. Therefore, the need to clarify the scientific mechanism of medicinal plants considered to have a physiological effect is rapidly becoming more urgent \[[@B19]\]. Additionally, these medicinal plants are also an important source of new chemicals with potential therapeutic effects.

*α*-Pinene is an organic terpene compound, which is contained in the oil of coniferous trees, and is the major monoterpene in pine trees \[[@B73]\]. *α*-Pinene is widely used as a food-flavouring ingredient \[[@B61], [@B65]\] and has been approved as a safe food additive by the U.S. Food and Drug Administration \[[@B76]\]. In addition, *α*-pinene is also contained in essential oils such as in rosemary (*Rosmarinus officinalis*) oil,*Eucalyptus* oil, camphor,*Bupleurum fruiticescens*,*Psidium*, and*Opuntia humifusa*. Indeed, *α*-pinene is considered to have a physiological effect on humans \[[@B22], [@B23]\], and essential oils containing *α*-pinene have been used to treat several diseases \[[@B48]\]. However, in humans, odours may lead to behavioural and cognitive changes, so careful interpretation is necessary. Inhalation of essential oils transfers signals from the olfactory system to the brain, and the brain regulates anxiety, depression, and mood disorders by secreting neurotransmitters such as serotonin and dopamine \[[@B43]\]. Therefore, various plant-derived essential oils have traditionally been used to treat psychiatric disorders such as depression, anxiety neurosis, attention-deficit hyperactivity disorder, and bipolar disorder. In addition, it has been reported that *α*-pinene also has anti-inflammatory \[[@B45], [@B86]\], antidepressant \[[@B1]\], anticonvulsant \[[@B15]\], antioxidant \[[@B74]\], antitumoral \[[@B20]\], and antinociceptive effects \[[@B31]\]. In recent years, it has been reported that inhalation of *α*-pinene has anxiolytic effects on mice during the elevated plus maze test \[[@B69]\]. Inhalation of *α*-pinene also leads to the accumulation of *α*-pinene in the brain. Furthermore, it has been shown that inhalation of *α*-pinene significantly increases rapid eye movement in rats during sleep \[[@B82]\]. Although *α*-pinene reportedly acts on rodents\' nerves by inhalation, it has not been investigated how *α*-pinene affects psychiatric-like behavioural abnormalities. Considering that *α*-pinene acts on the nervous system, *α*-pinene may be a potential therapeutic agent for psychoneurotic diseases including schizophrenia.

N-methyl-D-aspartate (NMDA) receptor antagonists such as dizocilpine (MK-801) are widely used for animal models of schizophrenia \[[@B54]--[@B39]\]. Administration of MK-801 alters the glutamatergic system in animal models and causes positive symptoms, negative symptoms, and cognitive impairment, similar to those seen in schizophrenia \[[@B4]--[@B18]\]. Many studies have reported the involvement of glutamatergic neurotransmission dysfunction via NMDA receptors in the pathophysiology of schizophrenia \[[@B33]--[@B42]\]. It is well established that the NMDA receptor plays an important role in the pathogenesis and pharmacological treatment of schizophrenia \[[@B26]--[@B18], [@B34]\]. Thus, when a novel compound relieves MK-801-induced behavioural abnormalities, a range of tests can be widely used to evaluate its preclinical utility as a potential antipsychotic \[[@B21]--[@B59]\].

This study aimed to evaluate whether inhalation of *α*-pinene suppresses schizophrenia-like behaviour abnormalities induced by MK-801. We investigated whether MK-801-induced abnormal behaviours would be suppressed by preexposure to *α*-pinene through a series of behavioural experiments.

2. Experimental Procedures {#sec2}
==========================

2.1. Animals {#sec2.1}
------------

We used 15-week-old male mice (C57BL/6) for the experiments. We purchased the animals from Charles River Laboratories (Kanagawa, Japan) and housed them in cages with food and water provided*ad libitum* under a 12 h light/dark cycle at 23--26°C. We made every effort to minimize the number of animals used and their suffering. These experiments complied with the U.S. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised in 1996) and were approved by the Committee for Animal Experiments at Kawasaki Medical School Advanced Research Center.

2.2. Drug Administration {#sec2.2}
------------------------

(+)-MK-801 (dizocilpine hydrogen maleate; 130-17381, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was diluted in saline at concentrations of 0.1 mg/mL and administered intraperitoneally (i.p.) in a volume of 0.2 mg/kg. This dose was selected on the basis of previous studies showing a schizophrenia-related deficient effect of MK-801 at 0.2 mg/kg in mice \[[@B57]--[@B11]\].

2.3. Inhalation of *α*-Pinene {#sec2.3}
-----------------------------

*α*-Pinene was acquired from FUJIFILM Wako Pure Chemical Corporation (169-21242). Additionally, saline was used as a control. The inhalation apparatus was the same as that used in a previous study \[[@B77]\]. Inhalation of the odour was carried out in a sealed container. A piece of absorbent cotton (4 × 4 cm) impregnated with 2 mL of *α*-pinene was placed in a stainless-steel container (60 × 60 × 35 mm) capped by a lid with holes. The mice were unable to lick or touch the cotton. The stainless-steel container was placed in a new breeding cage (235 × 325 × 170 mm) surrounded by two larger cages (292 × 440 × 200 mm). Approximately 20 min after the cotton placement, the mice were placed in the internal cage for 30 min. Control group mice were placed in the same container without the *α*-pinene. After 30 min, the mice received either a dose of MK-801 or saline. The test was started 30 min after MK-801 treatment.

2.4. Behavioural Tests {#sec2.4}
----------------------

All behavioural experiments were performed during the light phase (9:00--16:00). We tested mice in a random order. After testing, the apparatus was cleaned with 70% ethanol and 80 ppm super hypochlorous water to prevent any bias due to olfactory cues \[[@B38]\]. Animals were randomly selected and divided, according to a table of random numbers, into four groups: a control (inhaled saline, administered saline), MK-801 group (inhaled saline, administered MK-801), MK-801 + *α*-pinene group (inhaled *α*-pinene, administered MK-801), and *α*-pinene group ((inhaled *α*-pinene, administered saline). Each animal was subjected to the open field test only once (n = 8 animals per group). Next, the animals were randomly divided into three groups: a control group, MK-801 group, and MK-801 + *α*-pinene group. Each animal was subjected to the locomotor activity test, elevated plus maze test, Y-maze test, hot plate test, neurological screening, and tail suspension test only once (n = 10 animals per group).

2.5. Locomotor Activity Test {#sec2.5}
----------------------------

To assess whether exposure to *α*-pinene induced motor impairment or not, we examined locomotor activity under odour exposure. For measurements of locomotor activity, the mice were acclimated to the single housing environment (235 mm × 325 mm × 170 mm) for 3 h. Locomotor activity data were measured using a photobeam activity system (ACTIMO-100; BRC Co., Nagoya, Aichi, Japan). Sensors were located every 2 cm along the floor of the enclosure. Activity counts were expressed as the number of ambulations recorded at 10-min intervals. Mice were placed into photobeam activity arenas for 60 min before those in the MK-801 or saline groups were administered an injection \[[@B66]\]. Locomotion was measured for 3 h. "Control" group was treated with dH~2~O (inhalation) during the test period. "MK-801" group was treated with MK-801 (i.p.) and dH~2~O (inhalation) during the test period. "MK-801 + *α*-pinene" group was treated with MK-801 (i.p.) and *α*-pinene (inhalation) during the test period.

2.6. Open Field Test {#sec2.6}
--------------------

In the open field test, each mouse was placed at the centre of the apparatus, consisting of a square area surrounded by high walls (40 × 40 × 40 cm). The total distance travelled (m) and the time spent in the central area (s) were recorded \[[@B46]\]. The central area was defined as the 20 × 20-cm area located at the centre of the field. The test chamber was illuminated at 100 lux. Data were collected over a 30-min period. Data analysis was performed automatically using video tracking software (ANY-MAZE, Stoelting Co., Wood Dale, IL, USA).

2.7. Elevated Plus Maze Test {#sec2.7}
----------------------------

The apparatus consisted of two open arms (8 × 25 cm) and two closed arms of the same size with 30 cm-high transparent walls, similar to previous studies \[[@B3], [@B55]\]. The arms were made of white plastic plates and elevated to a height of 40 cm above the floor. Arms of the same type were located opposite each other. Each mouse was placed at the central square of the maze, facing one of the closed arms, and was allowed to move freely between the two arms for 10 min. The number of arm entries, distance travelled (m), and time (s) spent in the open arms were video recorded and analysed using the ANY-MAZE software.

2.8. Y-Maze Test {#sec2.8}
----------------

Spatial working memory was measured using a Y-maze apparatus (arm length: 40 cm, arm bottom width: 3 cm, arm upper width: 10 cm, wall height: 12 cm). The protocol was similar to that used in a previous study \[[@B80]\]. Mice were placed at the centre of the Y-maze field. Visual cues were placed around the maze in the testing room and were constant throughout the testing sessions. Mice were examined with no prior learning. The number of entries and alterations was recorded and analysed automatically using the ANY-MAZE software. Data were collected for 10 min.

2.9. Hot Plate Test {#sec2.9}
-------------------

The hot plate test was used to evaluate the nociception or sensitivity to a painful stimulus \[[@B78]\]. It consisted of an electrically heated surface and an open Plexiglass box (20 × 20 × 30 cm) to contain the animals. Mice were placed on a hot plate at 55.0 ± 0.3°C, and the latency to the first hind-paw response was recorded. The hind-paw responses counted foot shakes or paw licks. A latency period of 30 s was defined as complete analgesia and used as the cut-off time to prevent tissue injuries.

2.10. Neurological Screening {#sec2.10}
----------------------------

Neuromuscular strength was examined using the grip strength test according to a previous study \[[@B52]\]. A grip strength metre was used to assess forelimb grip strength. Mice were lifted and held by the tail such that their forepaws could grasp a wire grid; they were then pulled backward gently until they released the grid. The peak force applied by the forelimbs was recorded in Newtons (cN).

2.11. Tail Suspension Test {#sec2.11}
--------------------------

Each mouse was suspended by the tail at 60 cm above the floor, in a white plastic chamber, using adhesive tape placed \<1 cm from the tip of the tail. Mouse behaviour was recorded for 6 min. Images were captured via a video camera, and immobility time was measured \[[@B46]\]. In this test, the 'immobile period\' was defined as the period when the animals stopped struggling for ≥ 1 s. Data acquisition and analysis were performed automatically using the ANY-MAZE software.

2.12. Statistical Analyses of Behavioural Test Results {#sec2.12}
------------------------------------------------------

Data were analysed using one-way analysis of variance (ANOVA) followed by Tukey\'s test, two-way repeated measures ANOVA followed by Fisher\'s LSD test, Student\'s t-test, or paired t-test. A p-value of \< 0.05 was regarded as statistically significant. Data are presented as box plots.

3. Results {#sec3}
==========

3.1. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Locomotor Activity Test {#sec3.1}
---------------------------------------------------------------------------------------------

First, we tested whether *α*-pinene affects locomotor activity. Mice were pretreated with *α*-pinene before administration of MK-801. Pretreatment with *α*-pinene reduced basal activity ([Figure 1(a)](#fig1){ref-type="fig"},*F*~17,459~ = 10.07, p \< 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + *α*-pinene, p \< 0.001, MK-801 vs. MK-801 + *α*-pinene, p = 1.0, B,*F*~2,29~ = 7.348, p = 0.003; control vs. MK-801, p = 0.164; control vs. MK-801 + *α*-pinene, p = 0.143, MK-801 vs. MK-801 + *α*-pinene, p = 0.002). MK-801, an NMDA receptor antagonist, increases locomotor activity \[[@B12]\]. As shown in [Figure 1(a)](#fig1){ref-type="fig"}, the injection with MK-801 resulted in a robust increase in locomotor activity, which lasted for a further 120 min ([Figure 1(a)](#fig1){ref-type="fig"}). While the *α*-pinene pretreatment had a clear effect on basal activity, there was no effect on the MK-801-induced locomotor activity (Figures [1(a)](#fig1){ref-type="fig"} and [1(c)](#fig1){ref-type="fig"},*F*~2,29~ = 15.134, p \< 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + *α*-pinene, p \< 0.001, MK-801 vs. MK-801 + *α*-pinene, p = 0.654).

3.2. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Open Field Test {#sec3.2}
-------------------------------------------------------------------------------------

In the open field test, we observed no significant difference in the total distance travelled between mice exposed to only *α*-pinene and control mice ([Figure 2(a)](#fig2){ref-type="fig"},*F*~15,140~ = 2.275, p = 0.007; control vs. MK-801, p \< 0.001; control vs. MK-801 + *α*-pinene, p = 0.008, control vs. *α*-pinene, p = 1.0, MK-801 vs. MK-801 + *α*-pinene, p = 1.0, MK-801 vs. *α*-pinene, p \< 0.001, MK-801 + *α*-pinene vs. *α*-pinene, p = 0.007, [Figure 2(c)](#fig2){ref-type="fig"},*F*~3,31~ = 5.762, p = 0.003; control vs. MK-801, p = 0.012; control vs. MK-801 + *α*-pinene, p = 0.026, control vs. *α*-pinene, p = 0.952, MK-801 vs. MK-801 + *α*-pinene, p = 0.99, MK-801 vs. *α*-pinene, p = 0.043, MK-801 + *α*-pinene vs. *α*-pinene, p = 0.083). No differences were observed in the time spent in the central area between mice exposed to only *α*-pinene and control mice ([Figure 2(b)](#fig2){ref-type="fig"},*F*~15,140~ = 1.133, p = 0.333; control vs. MK-801, p = 0.002; control vs. MK-801 + *α*-pinene, p = 1.0, control vs. *α*-pinene, p = 1.0, MK-801 vs. MK-801 + *α*-pinene, p = 0.013, MK-801 vs. *α*-pinene, p = 0.006, MK-801 + *α*-pinene vs. *α*-pinene, p = 1.0, [Figure 2(d)](#fig2){ref-type="fig"},*F*~3,31~ = 7.186, p = 0.001; control vs. MK-801, p = 0.002; control vs. MK-801 + *α*-pinene, p = 0.864, control vs. *α*-pinene, p = 0.966, MK-801 vs. MK-801 + *α*-pinene, p = 0.011, MK-801 vs. *α*-pinene, p = 0.005, MK-801 + *α*-pinene vs. *α*-pinene, p = 0.989).

Administration of MK-801 markedly increased locomotor activity in mice (Figures [2(a)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). Similarly, administration of MK-801 markedly increased locomotor activity in mice preexposed to *α*-pinene (Figures [2(a)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). We observed no significant difference in the MK-801-induced hyperlocomotion between mice preexposed to *α*-pinene and those exposed to saline.

The time spent in the central area was significantly higher in mice administered MK-801 than in control mice (Figures [2(b)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}). Pretreatment with *α*-pinene significantly attenuated the MK-801-induced longer time spent in the central area (Figures [2(b)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}).

3.3. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Elevated Plus Maze Test {#sec3.3}
---------------------------------------------------------------------------------------------

In the elevated plus maze test, we evaluated anxiety-like behaviour in mice administered MK-801 after preexposure to *α*-pinene. Administration of MK-801 markedly increased the total distance travelled in mice preexposed to saline or *α*-pinene ([Figure 3(a)](#fig3){ref-type="fig"},*F*~2,28~ = 14.157, p \< 0.001; control vs. MK-801, p \< 0.001; control vs. MK-801 + *α*-pinene, p = 0.007, MK-801 vs. MK-801 + *α*-pinene, p = 0.18).

Mice administered MK-801 had a significantly higher number of entries to open arms than did the control mice ([Figure 3(b)](#fig3){ref-type="fig"},*F*~2,28~ = 8.342, p = 0.002; control vs. MK-801, p = 0.003; control vs. MK-801 + *α*-pinene, p = 0.007, MK-801 vs. MK-801 + *α*-pinene, p = 0.942). Similarly, mice administered MK-801 spent markedly increased time in the open arms than did the control mice ([Figure 3(c)](#fig3){ref-type="fig"},*F*~2,28~ = 9.183, p = 0.001; control vs. MK-801, p = 0.001; control vs. MK-801 + *α*-pinene, p = 0.039, MK-801 vs. MK-801 + *α*-pinene, p = 0.269).

No differences were observed in the total distance travelled, the number of total entries into open arms, and the time spent in open arms between mice administered MK-801 exposed to *α*-pinene or exposed to saline.

3.4. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Y-Maze Test {#sec3.4}
---------------------------------------------------------------------------------

We examined the effect of *α*-pinene on the short-term spatial working memory of mice administered MK-801 by monitoring spontaneous alteration behaviour in the Y-maze test. Administration of MK-801 markedly increased locomotor activity in mice ([Figure 4(a)](#fig4){ref-type="fig"},*F*~2,28~ = 13.284, p \< 0.001; control vs. MK-801, p \< 0.001; control vs. MK-801 + *α*-pinene, p = 0.191, MK-801 vs. MK-801 + *α*-pinene, p = 0.004). Similarly, administration of MK-801 markedly increased the number of arm entries ([Figure 4(b)](#fig4){ref-type="fig"},*F*~2,28~ = 17.62, p \< 0.001; control vs. MK-801, p \< 0.001; control vs. MK-801 + *α*-pinene, p = 0.435, MK-801 vs. MK-801 + *α*-pinene, p \< 0.001). There were no significant differences between control mice and mice administered MK-801 preexposed to *α*-pinene in the total distance travelled ([Figure 4(a)](#fig4){ref-type="fig"}) and the number of arm entries ([Figure 4(b)](#fig4){ref-type="fig"}). No differences were observed in the alteration percentage among the three groups ([Figure 4(c)](#fig4){ref-type="fig"},*F*~2,28~ = 1.086, p = 0.356; control vs. MK-801, p = 0.326; control vs. MK-801 + *α*-pinene, p = 0.683, MK-801 vs. MK-801 + *α*-pinene, p = 0.73).

3.5. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Hot Plate Test and Neuromuscular Strength Test {#sec3.5}
--------------------------------------------------------------------------------------------------------------------

We examined the effect of *α*-pinene on sensitivity to a painful stimulus in the hot plate test. Administration of MK-801 markedly decreased latency for the mice to lick their front paw ([Figure 5(a)](#fig5){ref-type="fig"},*F*~2,28~ = 21.681, p \< 0.001; control vs. MK-801, p \< 0.001; control vs. MK-801 + *α*-pinene, p \< 0.001, MK-801 vs. MK-801 + *α*-pinene, p = 0.4569). All mice administered MK-801 appeared to have a significantly higher pain threshold than mice administered saline ([Figure 5(a)](#fig5){ref-type="fig"}). No differences were observed in latency between mice administered MK-801 preexposed to *α*-pinene and exposed to saline.

We compared the neuromuscular strength of mice preexposed to *α*-pinene and mice preexposed to saline administered MK-801. No differences were observed in grip strength among the three groups ([Figure 5(b)](#fig5){ref-type="fig"},*F*~2,28~ = 1.622, p = 0.217; control vs. MK-801, p = 0.99; control vs. MK-801 + *α*-pinene, p = 0.306, MK-801 vs. MK-801 + *α*-pinene, p = 0.264).

3.6. Effect of *α*-Pinene on MK-801-Induced Abnormal Behaviour in the Tail Suspension Test {#sec3.6}
------------------------------------------------------------------------------------------

We evaluated depressive-like behaviour in mice administered MK-801 after *α*-pinene inhalation. In the tail suspension test, we found no significant differences among the three groups ([Figure 6(a)](#fig6){ref-type="fig"},*F*~2,28~ = 1.247, p = 0.304; control vs. MK-801, p = 0.284; control vs. MK-801 + *α*-pinene, p = 0.576, MK-801 vs. MK-801 + *α*-pinene, p = 0.838, B,*F*~2,28~ = 0.109, p = 0.897; control vs. MK-801, p = 0.398; control vs. MK-801 + *α*-pinene, p = 0.965, MK-801 vs. MK-801 + *α*-pinene, p = 1.0).

4. Discussion {#sec4}
=============

In this study, we evaluated the ability of *α*-pinene, which is widely used for food flavouring, to suppress and treat abnormal behaviour in a MK-801-induced mental disease mouse model. We investigated whether abnormal behaviour induced by administration of MK-801 would be alleviated by inhalation of *α*-pinene by conducting the open field, Y-maze, tail suspension, and elevated plus maze tests. The main finding of this study was that inhalation of *α*-pinene significantly reduced the abnormal behaviour of mice (hyperactivity and decreased anxiety-like behaviours) induced by MK-801 administration. To our knowledge, this is the first report that inhalation of *α*-pinene can reduce behavioural changes induced by NMDA receptor antagonists. Therefore, our findings indicate that *α*-pinene has potential antipsychotic activity in animal models of schizophrenia.

Open field testing is a useful behavioural experiment that is widely used to evaluate animal spontaneous activity and anxiety-like behaviour \[[@B5], [@B64]\]. It has been reported that spontaneous activity decreases by intraperitoneal administration of *α*-pinene to rats \[[@B84]\]. However, in the open field test, the amount of activity did not decrease in mice that were preexposed to *α*-pinene. However, during inhalation of *α*-pinene, a decrease in activity was confirmed in the locomotor activity test. Differences in these results are presumed to be due to differences in animal species, methods of administering *α*-pinene, concentration of administration, and inhalation time.

Similar behaviour was observed in this study, as it has been shown that administration of MK-801 in rodents increases activity in open field tests \[[@B17], [@B63]\]. However, *α*-pinene did not have the effect of suppressing the increase in activity in the open field test and locomotor activity test. In contrast, inhalation of *α*-pinene suppressed the MK-801-induced decrease in anxiety-like behaviour. This may be because the cognitive function of mice was not reduced by the sedative effect of *α*-pinene \[[@B40]\]. Although further research is needed to elucidate the clear mechanism, this experimental result strongly suggests that *α*-pinene reduces abnormal behaviours induced by MK-801.

As described in the introduction section, several studies have already reported the effects of inhalation of *α*-pinene \[[@B43], [@B48], [@B1], [@B69]\]. It has not been reported that inhalation of *α*-pinene suppresses psychiatric disorder-like behaviour. The purpose of this study is to clarify whether MK-801 induced behavioural abnormalities can be suppressed by inhalation of *α*-pinene. Therefore, the group who only inhaled *α*-pinene was excluded.

MK-801 administration is considered to cause an increase in activity level and a decrease in anxiety-like behaviour in the elevated plus maze \[[@B71], [@B6]\]. Moreover, in this study, administration of MK-801 caused an increase in activity level and a decrease in anxiety-like behaviour in mice. *α*-Pinene did not alleviate behavioural abnormalities in mice induced by administration of MK-801 in this experiment.

The spontaneous alteration score in the Y-maze test is an index of working memory and spatial cognitive function \[[@B13], [@B72]\]. Administration of MK-801 reportedly reduces spontaneous alteration scores in rodents \[[@B50], [@B56]\]. In this study, the spontaneous alteration scores of MK-801 treated mice tended to be lower than those of control mice, but no significant difference was found among the three groups. In fact, it has been reported that spontaneous alteration does not decrease significantly by MK-801 administration \[[@B29]\]. Differences in these results are presumed to be due to differences in mouse strain or MK-801 administration concentration. However, in this Y-maze test, MK-801 caused an increase in activity level in mice, while *α*-pinene inhibited the increase in activity level induced by MK-801.

It is known that NMDA receptors are involved in pain associated with peripheral tissues or nerve injuries \[[@B62]--[@B47]\]. It has already been reported that administration of MK-801 to mice causes an antinociceptive effect in the hot plate test \[[@B49]\]. The present study also showed that MK-801 has an analgesic effect in acute pain as previously reported. *α*-Pinene did not affect the MK-801-induced analgesic effect. Since the tail flick test and the acetic acid writhing test were not carried out and although details of the influence of *α*-pinene are unknown, *α*-pinene may not affect the peripheral sensory nervous system.

Several basic and clinical studies have shown that the glutamatergic system is widely involved in the pathophysiology of depression \[[@B60], [@B51]\]. Therefore, administration of the NMDA receptor antagonist MK-801 exerts an antidepressant effect in an animal model of depression \[[@B44], [@B68]\]. However, in this study, MK-801 administered mice showed no antidepressive behaviour. In this study, we did not use a mouse model of depression under chronic stress as was used in previous reports \[[@B44], [@B68]\]. The difference in results is presumed to be due to the mouse model used. At least our study result showed that *α*-pinene may not exert antidepressant effects against sudden stress. In fact, in order to investigate the antidepressant effect of *α*-pinene, studies using mouse models of depression are necessary.

It has been reported that inhalation of *α*-pinene causes anxiolytic effects on mice during the elevated plus maze test \[[@B69]\] and antidepressant effects on rats in the forced swim test \[[@B37]\]. However, these results are from daily inhalation. In this experiment, we did not conduct some behavioural experiments using the group that inhaled only *α*-pinene for 30 minutes. Considering previous studies, it is speculated that *α*-pinene inhalation for only 30 minutes does not affect the normal behaviour of mice, but further studies are needed to clarify these observations.

*α*-Pinene promotes the function of the GABA-A receptor and increases the postsynaptic GABA-dependent chloride flow in GABA-A receptors \[[@B2]\]. Furthermore, it has been reported that in mice, after oral ingestion, *α*-pinene binds to the benzodiazepine site of the GABA receptor and becomes a useful hypnotic agent \[[@B83]\]. As reported above, it is presumed that *α*-pinene acts on the brain through stimulation of the GABA receptor \[[@B35]\]. Benzodiazepines such as diazepam also exert sedative and anxiolytic effects via GABA receptors \[[@B9]\]. Conversely, monoterpenes such as *α*-pinene, citronellal, citronellol, and myrcene are reported NMDA receptors antagonists \[[@B28]\]. That is, *α*-pinene is considered to exert physiological effects such as anxiolytic and antioxidant effects through these mechanisms.

Importantly, it is not clear how odour molecules act on nerves through inhalation. One likely hypothesis is that the volatile compound *α*-pinene acts pharmacologically by entering the bloodstream through the mucosa of the nose or lung. The skin permeability of a drug has a high correlation with the lipid solubility or lipophilicity of the drug \[[@B70]\]. Drugs with molecular weights up to 100 kDa are easily absorbed from the nasal mucosa \[[@B24]\]. Since *α*-pinene has a low molecular weight and high lipophilicity \[[@B22], [@B23]\], it is considered that it is easily absorbed from the nasal mucosa. For the same reasons, it is also expected to have good permeability in brain tissue. In mice, inhaled *α*-pinene has been shown to reach the brain \[[@B69]\]. From these reports, it is reasonable to hypothesise that inhaled *α*-pinene acts on the nerves and alleviates MK-801-induced neural activity abnormality. However, to our knowledge, there are currently no data on the pharmacokinetic interaction between *α*-pinene and MK-801. Further research is needed to clarify these issues.

This study is the first to analyse the effects of *α*-pinene inhalation on MK-801-induced behavioural abnormalities in mice through a series of behavioural tests. Our findings show that the odour of *α*-pinene-containing foodstuffs and essential oils has the effect of alleviating behavioural abnormalities associated with schizophrenia and at the same time presents the scientific basis for the physiological action of odours.

5. Conclusions {#sec5}
==============

In conclusion, inhalation of *α*-pinene reduces MK-801-induced psychiatric-like behavioural abnormalities in mice. Our results suggest that inhalation of essential oils containing *α*-pinene acts on nerves and suppresses abnormal activity increase of nerve cells. Thus, *α*-pinene can be a useful natural substance for the treatment and prevention of neuropsychiatric disorders.
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![Effect of *α*-pinene on MK-801-induced hyperlocomotion in the locomotor activity test. Results of the locomotor activity test in the three groups. Spontaneous locomotor activity in each 10-min period (a). After 60 min, animals were injected with MK-801 or saline, and locomotor activity was assessed for 180 min. Total beam breaks for 60 min before injection of MK-801 or saline (b). Total beam breaks for 120 min after injection of MK-801 or saline (c). Data are presented as the mean ± SEM (a), or box plots (b, c). *∗*, significant difference among groups (p \< 0.05). The p values were calculated using two-way repeated measures analysis of variance in (a) and Student\'s t-test in ((b), (c)).](ECAM2019-2745453.001){#fig1}

![Effect of *α*-pinene on MK-801-induced hyperlocomotion in the open field test. Graphs showing the distance travelled (a) and time spent in the central area (b) in each 5 min-period of the open field test. Graphs showing the total distance travelled (c) and total time spent in the central area (d) in the open field test. All data are presented as box plots. *∗*, significant difference among groups (p \< 0.05). The p-values were calculated using two-way repeated measures analysis of variance in (a, b) and one-way analysis of variance in ((c), (d)).](ECAM2019-2745453.002){#fig2}

![Effect of *α*-pinene on MK-801-induced abnormal behaviour in the elevated plus maze test. Graphs showing the total distance travelled (a), the number of open arm entries (b), and the time spent in the open arms (c) in the elevated plus maze test. All data are presented as box plots. *∗*, significant difference among groups (p \< 0.05). The p-values were calculated using one-way analysis of variance in ((a)--(c)).](ECAM2019-2745453.003){#fig3}

![Effect of *α*-pinene on MK-801 induced cognitive deficits in the Y-maze test. Graphs showing the total distance travelled (a), total number of arm entries (b), and percentage of alterations (c). All data are presented as box plots. *∗*, significant difference among groups (p \< 0.05). The p-values were calculated using the one-way analysis of variance in ((a)--(c)).](ECAM2019-2745453.004){#fig4}

![Effect of *α*-pinene on MK-801-induced antinociceptive effects in the hot plate test and grip strength test. (a) Latency to the first fore- or hind-paw response in the hot plate test. (b) Grip strength. All data are presented as box plots. *∗*, significant difference among groups (p \< 0.05). The p-values were calculated using one-way analysis of variance in ((a)--(c)).](ECAM2019-2745453.005){#fig5}

![Effect of *α*-pinene on MK-801-induced antidepressant behaviour in the tail suspension test. Graphs showing the proportion of total time spent immobile (a) and the proportion of time spent immobile in each 1-min period (b) in the tail suspension test. All data are presented as box plots. *∗*, significant difference among groups (p \< 0.05). The p-values were calculated using one-way analysis of variance in (a) and two-way repeated measures analysis of variance in (b).](ECAM2019-2745453.006){#fig6}
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